Vertex Pharmaceuticals, Inc. (VRTX) Reports Q2 Loss of 85c, Beats by 10c
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $516.44 -1.77%
Financial Fact:
Total revenues: 413.78M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total revenues: 413.78M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q2 EPS of ($0.85), $0.10 better than the analyst estimate of ($0.95). Revenue for the quarter came in at $114.42 million, versus $31.62 million reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital on Vertex (VRTX): 'SION Overhang Cleared; We Would Remain Buyers'
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Vertex (VRTX) PT Raised to $562 at Wolfe Research
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
